Webinar | September 22, 2022

Evolution Of Cell & Gene Therapy In China: The Case For Universal CAR-T

Source: Novotech

China now represents 60% of clinical development in CAR-T therapy development globally: what have we learned to date and where are future opportunities?

access the Webinar!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Novotech